Bedaquiline Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Characterization of < em > Mycobacterium abscessus < /em > colony-biofilms based on bi-dimensional images
Antimicrob Agents Chemother. 2023 Aug 11:e0040223. doi: 10.1128/aac.00402-23. Online ahead of print.ABSTRACTMycobacterium abscessus biofilm aggregates have been shown in the lungs of cystic fibrosis patients and are often tolerant to drugs. Herein, we analyzed bi-dimensional images of either fluorescent or Congo red-stained M. abscessus colony-biofilms grown on a membrane to monitor growth and shape of M. abscessus smooth and rough variants. These colony-biofilms responded differently to rifabutin and bedaquiline, thus highlighting the importance of the morphotype to properly address antibiotic treatment in patients with b...
Source: Antimicrobial Agents and Chemotherapy - August 11, 2023 Category: Microbiology Authors: John Jairo Aguilera-Correa Yves-Marie Boudehen Laurent Kremer Source Type: research

Lung microenvironments harbor < em > Mycobacterium tuberculosis < /em > phenotypes with distinct treatment responses
Antimicrob Agents Chemother. 2023 Aug 11:e0028423. doi: 10.1128/aac.00284-23. Online ahead of print.ABSTRACTTuberculosis lung lesions are complex and harbor heterogeneous microenvironments that influence antibiotic effectiveness. Major strides have been made recently in understanding drug pharmacokinetics in pulmonary lesions, but the bacterial phenotypes that arise under these conditions and their contribution to drug tolerance are poorly understood. A pharmacodynamic marker called the RS ratio® quantifies ongoing rRNA synthesis based on the abundance of newly synthesized precursor rRNA relative to mature structural rRNA...
Source: Antimicrobial Agents and Chemotherapy - August 11, 2023 Category: Microbiology Authors: Nicholas D Walter Jackie P Ernest Christian Dide-Agossou Allison A Bauman Michelle E Ramey Karen Rossmassler Lisa M Massoudi Samantha Pauly Reem Al Mubarak Martin I Voskuil Firat Kaya Jansy P Sarathy Matthew D Zimmerman V éronique Dartois Brendan K Podel Source Type: research

Outcomes of bedaquiline containing regimen in the treatment of adults with drug resistant tuberculosis in a tertiary care centre of Rajasthan
This study was conducted to estimate treatment outcomes and adverse effects in patients with drug-resistant TB patients on bedaquiline-containing regimen. Patients after the pre-treatment evaluation were enrolled for bedaquiline-containing regimen. These patients were followed up for 18 months and the final outcome was assessed along with the adverse effects. It was found that 49 (84.4%) patients achieved culture conversion by three months and 54 (93.1%) achieved culture conversion by six months, 52 (83.81%) patients had favourable outcomes (cured, treatment completed) and 10 patients had unfavourable outcomes (died, lost ...
Source: Monaldi Archives for Chest Disease - August 8, 2023 Category: Respiratory Medicine Authors: Roshni Mary Prince Suman Khangarot Qazi Faizanul Haque Anish Mittal Ramdhan Somani Mansha Grover Source Type: research

The Safety and Efficacy of Prolonged Use of Bedaquiline for the Treatment of Patients with Pulmonary Multi-Drug Resistant/Rifampin-Resistant Tuberculosis: A Prospective, Cohort Study in China
(Source: Infection and Drug Resistance)
Source: Infection and Drug Resistance - August 7, 2023 Category: Infectious Diseases Tags: Infection and Drug Resistance Source Type: research

New advances in the treatments of drug-resistant tuberculosis
Expert Rev Anti Infect Ther. 2023 Jul 21. doi: 10.1080/14787210.2023.2240022. Online ahead of print.ABSTRACTINTRODUCTION: TB is associated with high mortality and morbidity among infected individuals and a high transmission rate from person to person. Despite the availability of vaccines and several anti-TB,TB infection continues to increase. Global resistance to TB remains the greatest challenge. There has not been extensive research into a new treatment and management strategy for TB resistance therapy. This review is based on a review of new advances and alternative drugs in the treatment of drug-resistant TB.AREAS COVE...
Source: Expert Review of Anti-Infective Therapy - July 21, 2023 Category: Infectious Diseases Authors: Mohanad Mahmoud Yurong Tan Source Type: research

Major drug company bends in battle over access to key TB treatment
In the latest twist in a prolonged battle over access to a lifesaving medicine for drug-resistant tuberculosis (TB), the pharmaceutical company Johnson & Johnson (J&J) has agreed not to enforce some of its patents on the drug, bedaquiline. The move will make generic versions available in many low- and middle-income countries (LMICs). The deal was announced yesterday by the United Nations–affiliated Stop TB Partnership, whose Global Drug Facility (GDF) purchases and makes TB drugs available at affordable prices to countries in need. J&J agreed to provide GDF with licenses enabling the or...
Source: Science of Aging Knowledge Environment - July 14, 2023 Category: Geriatrics Source Type: research

Cost-Effectiveness Analysis of Combined Chemotherapy Regimen Containing Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis in China
CONCLUSION: BR is shown to be cost effective. When the unit price of Bedaquiline reaches or falls below 57.21 yuan per unit, BR is expected to be the dominant strategy in China over CR.PMID:37424243 | DOI:10.3967/bes2023.061 (Source: Biomedical and Environmental Sciences : BES)
Source: Biomedical and Environmental Sciences : BES - July 10, 2023 Category: Biomedical Science Authors: Cai Hong Xu Ying Peng Qiu Zi Long He Dong Mei Hu Xiao Yue Zhong Dan Chen Yuan Yuan Xu Yan Lin Zhao Source Type: research